{"id":955821,"date":"2026-04-29T07:04:27","date_gmt":"2026-04-29T11:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-reports-2026-first-quarter-financial-results\/"},"modified":"2026-04-29T07:04:27","modified_gmt":"2026-04-29T11:04:27","slug":"amarin-reports-2026-first-quarter-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-reports-2026-first-quarter-financial-results\/","title":{"rendered":"Amarin Reports 2026 First Quarter Financial Results"},"content":{"rendered":"
\n

\n Total Revenue Increased Led by Higher International Sales<\/em>\n <\/p>\n

\n Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow<\/em>\n <\/p>\n

\n Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management <\/em>\n <\/p>\n

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).<\/p>\n

\u201cOur results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025,\u201d said Aaron Berg, President and Chief Executive Officer.<\/p>\n

\u201cThe promise of our fully-partnered international commercial strategy \u2013 anchored by our European-focused exclusive licensing and supply agreement with Recordati S.p.A. (Recordati) – was reflected in higher European product revenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was attributable to strong in-market demand for VAZKEPA\u00ae<\/sup> (icosapent ethyl) and the priority assigned by Recordati to expand the commercial reach for this proven therapy. While acknowledging that European sales will vary quarter to quarter, especially in the early days of this new partnership, these initial results are encouraging. Recordati has commenced commercial efforts of VAZKEPA in 10 countries, including a Q4 2025 launch in Italy, and plans to expand its distribution across Europe over the next several years. We are also seeing good growth from our active commercial partners outside of Europe.\u201d<\/p>\n

\u201cOur U.S. franchise continues to demonstrate remarkable resilience, where we have maintained our leading market share for VASCEPA\u00ae<\/sup> more than five years since the introduction of generics. Industry prescription data for Q1 2026 showed an overall increase in the icosapent ethyl (IPE) market while VASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that volumes will remain stable throughout 2026. Our streamlined U.S. operation remains an efficient, cash generating engine for our Company.\u201d\u00a0<\/p>\n

He continued, \u201cWe are encouraged by the 2026 American College of Cardiology (ACC) \/ American Heart Association (AHA)\/Multisociety Dyslipidemia Guideline Update from March of this year that supports the broader clinical role of IPE in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides. These guidelines shift CV care toward early, lifelong prevention and a more comprehensive risk approach beyond just lowering LDL cholesterol. In recognizing that high triglyceride levels contribute to CV events in many patients, this framework underscores the need for additional therapies beyond statins to address this care gap. This evolutionary perspective on CV risk management is timely and strengthens our position to address the burden of CV disease in patients and across the healthcare ecosystem.\u201d<\/p>\n

Mr. Berg concluded, \u201cWe have created a new version of Amarin \u2013 focused, leaner, and both financially and operationally stronger than at any time in our recent history. The growth initiatives we have undertaken and building industry tailwinds increasingly focused on the needs of patients with elevated triglycerides have positioned us well for 2026. Our team is executing with focus and discipline to achieve our objectives and deliver shareholder value, while continuing to work closely with Barclay\u2019s, our exclusive financial advisor, in exploring additional potential pathways to further enhance shareholder value. While there is still work to be done, we look forward to our future with confidence.\u201d\u00a0\u00a0\u00a0<\/p>\n

\n
\n Q1 2026 Financial Highlights <\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\n
\n ($ in millions)<\/em>
\n <\/strong>\n <\/td>\n		\n Q1 2026<\/strong>\n <\/td>\n\n Q1 2025<\/strong>\n <\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Total Net Revenue<\/td>\n$45.1<\/td>\n$42.0<\/td>\n7%<\/td>\n<\/tr>\n
Operating Expenses<\/td>\n$29.1<\/td>\n$41.9<\/td>\n(31)%<\/td>\n<\/tr>\n
Operating Loss
Operating Margin % *<\/td>\n		$(11.3)
(25)%<\/td>\n		$(16.8)
(40)%<\/td>\n		(32)%
NM<\/td>\n<\/tr>\n
Net Loss
Net Margin<\/td>\n		$(10.5)
(23)%<\/td>\n		$(15.7)
(37)%<\/td>\n		(33)%
NM<\/td>\n<\/tr>\n
Cash<\/td>\n$307.8<\/td>\n$281.8<\/td>\n9%<\/td>\n<\/tr>\n
\n * <\/em>
\n Operating margin is calculated as operating loss divided by total net revenue. <\/em>
\n
\n NM \u2013 Not Meaningful<\/em>\u00a0\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Peter Fishman, Amarin\u2019s Chief Financial Officer, said, \u201cWe are encouraged by our Q1 2026 performance under our new business model. We achieved higher total revenue, led by growth from our partners, and a continued decline in our operating expenses, both of which led to significantly narrowed losses compared to the same period last year. We remain on track to realize the approximately $70 million in cost savings and have incurred nearly all of the associated restructuring costs. Finally, we generated positive cash flow for the second consecutive quarter and continue to expect to be cash flow positive for full year 2026.\u201d<\/p>\n

\n Q1 2026 Financial Performance<\/strong>
\n
\n Comparisons to Q1 2025, unless otherwise stated <\/em>\n <\/p>\n

\n
\n Revenues<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n
\n
\n ($ in millions)<\/em>
\n <\/strong>\n <\/td>\n		\n Q1 2026<\/strong>\n <\/td>\n\n Q1 2025<\/strong>\n <\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Product Revenue, net:
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 U.S.
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Europe
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Rest-of-World (ROW)<\/td>\n		\n
$35.6
$4.9
$2.8<\/td>\n		\n
$35.7
$5.4
$0<\/td>\n		\n
(0)%
(9)%
NM<\/td>\n<\/tr>\n
Total Product Revenue, net<\/td>\n$43.3<\/td>\n$41.0<\/td>\n6%<\/td>\n<\/tr>\n
Licensing & Royalties<\/td>\n$1.8<\/td>\n$1.0<\/td>\n84%<\/td>\n<\/tr>\n
Total Net Revenue<\/td>\n$45.1<\/td>\n$42.0<\/td>\n7%<\/td>\n<\/tr>\n
\n NM – Not Meaningful<\/p>\n

<\/em>\n <\/td>\n<\/tr>\n<\/table>\n

\n Total Net Revenue:<\/strong> Increased $3.1 million, or 7%. U.S. sales of VASCEPA were consistent with the prior year period, benefitting from an increase in volume related to the regaining of exclusive status with a large national pharmacy benefit manager (PBM) beginning in Q3 2025. A slight decline in European revenue was attributable to moving to a partnered sales model in the second half of 2025, a transition that had yet to take effect in Q1 2025. Quarter-to-quarter European sales comparisons that reflect the partnership model with Recordati will commence in Q3 2026. Licensing and royalty revenue increased by 84% due to higher in-market sales generated by our international commercial sales partners.<\/p>\n

\n
\n Operating Expenses<\/u>
\n <\/strong>
\n
\n Comparisons to Q1 2025, unless otherwise stated <\/em>\n <\/p>\n\n\n\n\n\n\n\n\n
\n
\n ($ in millions)<\/em>
\n <\/strong>\n <\/td>\n		\n Q1 2026<\/strong>\n <\/td>\n\n Q1 2025<\/strong>\n <\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
COGS<\/td>\n$27.4<\/td>\n$16.9<\/td>\n62%<\/td>\n<\/tr>\n
SG&A<\/td>\n$21.1<\/td>\n$36.6<\/td>\n(42)%<\/td>\n<\/tr>\n
R&D<\/td>\n$4.7<\/td>\n$5.3<\/td>\n(12)%<\/td>\n<\/tr>\n
Restructuring<\/td>\n$3.3<\/td>\n—<\/td>\nNM<\/td>\n<\/tr>\n
Total Operating Expenses *<\/td>\n$29.1<\/td>\n$41.9<\/td>\n(31)%<\/td>\n<\/tr>\n
\n * <\/em>
\n Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses.<\/em>
\n
\n NM – Not Meaningful<\/em><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n Total Operating Expenses:<\/strong> Decreased $12.8 million, or 31%, primarily due to the impact of the June 2025 Global Restructuring that produced declines in Selling, General, and Administrative expenses (SG&A). Excluding the restructuring charge of $3.3 million (see discussion below<\/em>), Q1 2026 total operating expenses were $25.8 million, representing a decline of 38%.<\/p>\n

\n COGS:<\/strong> Increased $10.5 million, or 62%, reflecting increased product volumes to satisfy demand associated with our exclusive PBM relationship that took effect July 1, 2025 and shipments to ROW partners that did not exist in last year\u2019s first quarter.<\/p>\n

\n SG&A: <\/strong>Decreased $15.5 million, or 42%, primarily due to a reduction in costs pursuant to the Global Restructuring and other cost optimization initiatives, slightly offset by litigation settlements.<\/p>\n

\n R&D:<\/strong> Consistent with the prior year period.<\/p>\n

\n Restructuring: <\/strong>The Company recognized $3.3 million in Q1 2026 related to the continued implementation of the Global Restructuring associated with the execution of the Recordati Licensing Agreement announced in June 2025. The Company has incurred a total of $ 39.6 million of restructuring charges through Q1 2026, with the remaining nominal charges expected to be realized in Q2 2026.<\/p>\n

\n
\n Additional Q1 2026 Financial Information<\/u>
\n <\/strong>
\n
\n Comparisons to Q1 2025, unless otherwise stated <\/em>\n <\/p>\n

\n Operating Loss:<\/strong> Narrowed to $11.3 million from an operating loss of $16.8 million, an improvement of $5.4 million, or 32%. Operating loss in Q1 2026 included restructuring costs of $3.3 million compared to no such charges in Q1 2025.<\/p>\n

\n Net Loss: <\/strong>Improved to $10.5 million, or $(0.03) per share, from a net loss of $15.7 million, or $(0.04) per share.<\/p>\n

\n Cash:<\/strong> Reported aggregate cash and investments rose to $307.8 million as of March 31, 2026 compared to $302.6 million as of December 31, 2025.<\/p>\n

\n Debt:<\/strong> Remained debt free as of March 31, 2026.<\/p>\n

\n First Quarter 2026 Earnings Conference Call and Webcast Information<\/strong>
\n
Amarin will host a conference call on April 29, 2026, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the Company’s website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 543818. A replay of the webcast will be made available until October 29, 2026. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 53836. A replay of the call will also be available through the Company’s website shortly after the call.\u00a0<\/p>\n

\n About Amarin
<\/strong>Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world\u2019s leading cause of death, CVD.<\/p>\n

\n About VASCEPA\u00ae<\/sup>\/VAZKEPA\u00ae<\/sup> (icosapent ethyl) Capsules<\/strong>
\n
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug\u2019s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (\u2265500 mg\/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty-five million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Finland, England\/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria.<\/p>\n

\n United States Indications and Limitation of Use<\/strong>
\n
VASCEPA is indicated:\u00a0\u00a0<\/p>\n